Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

filibuvir

Known as: (6R)-6-Cyclopentyl-6-(2-(2,6-Diethylpyridin-4-yl)Ethyl)-3-((5,7-Dimethyl(1,2,4)Triazolo(1,5- A)Pyrimidin-2-yl)Methyl)-4-Hydroxy-5,6-Dihydro-2H-Pyran-2-One, 2H-Pyran-2-One, 6-Cyclopentyl-6-(2-(2,6-Diethyl-4-Pyridinyl)Ethyl)-3-((5,7-Dimethyl(1,2,4)Triazolo(1,5-A)Pyrimidin-2-yl)Methyl)-5,6-Dihydro-4-Hydroxy-, (6R)- 
A non-nucleoside polymerase inhibitor of the hepatitis C virus NS5B RNA-dependent RNA polymerase. Filibuvir binds to the non-catalytic Thumb 2 site… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Filibuvir, a potent non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp), has shown… Expand
  • figure 1
  • figure 2
  • figure 5
  • figure 6
  • figure 7
Is this relevant?
2014
2014
UNLABELLED Hepatitis C virus (HCV) is a genetically diverse virus with multiple genotypes exhibiting remarkable differences… Expand
  • figure 1
  • table 3
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Direct-acting antivirals (DAAs) targeting proteins encoded by the hepatitis C virus (HCV) genome have great potential for the… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2013
2013
GS-9669 is a highly optimized thumb site II nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, with a binding… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 4
Is this relevant?
2013
2013
Development of allosteric inhibitors into efficient drugs is hampered by their indirect mode-of-action and complex structure… Expand
Is this relevant?
2012
2012
Filibuvir and VX-222 are nonnucleoside inhibitors (NNIs) that bind to the thumb II allosteric pocket of the hepatitis C virus… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 5
Is this relevant?
2012
2012
Filibuvir (PF-00868554) is an investigational nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural 5B (NS5B) RNA… Expand
Is this relevant?
2011
2011
UNLABELLED More effective and better-tolerated therapies are needed for chronic hepatitis C virus (HCV) infection. Among the… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
Abstract Filibuvir (PF-868554), being developed by Pfizer, is an orally administered, non-nucleoside inhibitor of the HCV NS5B… Expand
Is this relevant?